



# FDA Disclaimer

The views and opinions presented here represent those of the speaker and should not be considered to represent advice or guidance on behalf of the U.S. Food and Drug Administration.

# eCTD

**Jonathan Resnick**

Electronic Submission Support Team  
Office of Business Informatics, CDER

April 4, 2017

# Poll Question

**How would you characterize your ability to submit your ANDA in proper eCTD format?**

## Topics Covered

- Important Submission Deadlines
- Gateway Acknowledgements
- Where Submission Issues Occur

## Deadlines for Required eCTD Submission

- **May 5, 2017:** ANDAs must be in eCTD format
- Do not send Paper and/or non-eCTD submissions after these deadlines!

## Deadlines for Required eCTD Submission

- Exemptions are outlined in the guidance
- Submissions that do not adhere to the requirements stated in the eCTD Guidance will be **not be filed or received**
- Please see the eCTD web page [www.fda.gov/ectd](http://www.fda.gov/ectd) for further information


## What Else?

- ✓ Must use Fillable Forms & Electronic Signatures within those forms
- ✓ Must use correct Lifecycle operators
  - Use the “Replace” lifecycle operator when updating content

# What Else?

- ✓ Must use Gateway for submissions 10GB and smaller

*Submissions larger than 10GB may come via the Gateway or USB drive*



\*See Transmission Specification for additional details



# Deadlines for Standardized Study data



- Studies that start after December 17, 2016 must be in standardized format for ANDA submissions

# Deadlines for Standardized Study Data



- **What** is the new requirement?
  - Studies that start after **December 17, 2016** must be in standardized format for ANDA submissions
  - See the Study Data Standards Resources page for more information

<http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm>

- **How** will we enforce it?
  - Technical Rejection Criteria for Study Data
  - Specifications for eCTD Validation Criteria

<http://www.fda.gov/ectd>

# Deadlines for Standardized Study Data



- **When** will we starting enforcing it?


CDER will start using the new validation criteria later this year

- **Where** can I find the guidance?

<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292334.pdf>

- Have Questions? Contact [eData@fda.hhs.gov](mailto:eData@fda.hhs.gov)

# Gateway Acknowledgements



# CDER Gateway Successful 3<sup>rd</sup> Acknowledgement



- Began May 31, 2016
- Applies only to NDA, ANDA, BLA, IND or DMF submissions
- Sent when the submission is validated and ready for division's review

# CDER Gateway Successful 3<sup>rd</sup> Acknowledgement



- This is in addition to the ESG Message Delivery Notification acknowledgement (first acknowledgement) and the Official Center acknowledgement (second acknowledgement)
- May be delayed if your submission fails validation and needs manual processing

# Where Submission Issues Occur

- Transmission to ESG is unsuccessful – 1<sup>st</sup> Acknowledgement
- CDER runs technical validation on submission and it fails – after 2<sup>nd</sup> Acknowledgement
- Division of Filing Review finds issues with content of application – after 3<sup>rd</sup> Acknowledgement

# Summary



- Important Submission Deadlines
  - **ANDAs Must be Submitted in eCTD Format May 5, 2017**
- Gateway Acknowledgements (three of them!)
  - **When** you receive them, **What** they mean
- Where Submission Issues Occur
  - **ESG Processing. CDER Processing. Division of Filing Review.**





# Thank You

**Jonathan Resnick**

CDER Electronic Submission Support Team

[eSub@fda.hhs.gov](mailto:eSub@fda.hhs.gov)

[www.fda.gov/ectd](http://www.fda.gov/ectd)

Please complete the session survey:

[surveymonkey.com/r/GDF-D1S08](https://surveymonkey.com/r/GDF-D1S08)